Drug Profile
FX 101
Alternative Names: FX-101Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Jericho Sciences
- Developer Jericho Sciences; North Carolina State University
- Class Antivirals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HIV infections
Most Recent Events
- 12 Sep 2023 FX 101 is still in preclinical development for HIV infections in USA (Jericho Sciences pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in HIV-infections in USA
- 28 Jul 2016 Preclinical trials in HIV infections in USA (unspecified route)